Manufacturer of Controlled Substances, Notice of Application: Noramco, Inc., 3627-3628 [2014-01158]

Download as PDF 3627 Federal Register / Vol. 79, No. 14 / Wednesday, January 22, 2014 / Notices for such registration pursuant to 21.U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application; Noramco, Inc. Pursuant to 21 CFR 1301.34 (a), this is notice that on December 3, 2013, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances: emcdonald on DSK67QTVN1PROD with NOTICES Phenylacetone (8501) .................. Thebaine (9333) ........................... Poppy Straw Concentrate (9670) Tapentadol (9780) ........................ BILLING CODE 4410–09–P Dated: January 14, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE [FR Doc. 2014–01156 Filed 1–21–14; 8:45 am] Schedule Drug Drug Enforcement Administration BILLING CODE 4410–09–P II II II II Importer of Controlled Substances; Notice of Registration; Noramco, Inc. DEPARTMENT OF JUSTICE By Notice dated September 27, 2013, and published in the Federal Register on October 25, 2013, 78 FR 64015, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4417, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: Drug Enforcement Administration The company plans to import the listed controlled substances to manufacture other controlled substances for distribution to the company’s customers. Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007) In reference to the non-narcotic raw material, any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 21, 2014. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements VerDate Mar<15>2010 16:00 Jan 21, 2014 Dated: January 14, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Jkt 232001 [FR Doc. 2014–01157 Filed 1–21–14; 8:45 am] Drug Schedule Phenylacetone (8501) .................. Opium, raw (9600) ....................... Poppy Straw Concentrate (9670) Tapentadol (9780) ........................ II II II II The company plans to import the Opium, raw (9600) and Poppy Straw Concentrate (9670) to manufacture other controlled substances. The company plans to import Tapentadol (9780) in intermediate form for the bulk manufacture of Tapentadol (9780) for distribution to its customers. The company plans to import Phenylacetone (8501) in bulk for the manufacture of a controlled substance. Comments and requests for hearings on application to import narcotic raw material are not appropriate. 72 FR 3417 (2007) No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Noramco, Inc., to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Noramco, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 Manufacturer of Controlled Substances, Notice of Application: Noramco, Inc. Pursuant to 21 CFR 1301.33(a), this is notice that on August 5, 2013, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the following basic classes of controlled substances: Drug Codeine-N-oxide (9053) ............... Dihydromorphine (9145) ............... Morphine-N-oxide (9307) ............. Amphetamine (1100) .................... Methylphenidate (1724) ................ Phenylacetone (8501) .................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Tapentadol (9780) ........................ Schedule I I I II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement E:\FR\FM\22JAN1.SGM 22JAN1 3628 Federal Register / Vol. 79, No. 14 / Wednesday, January 22, 2014 / Notices Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 24, 2014. Dated: January 14, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–01158 Filed 1–21–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OMB Number 1121–NEW] Agency Information Collection Activities: Proposed Collection; Comments Requested New Collection: Survey of Juveniles Charged in Adult Criminal Court, 2013 emcdonald on DSK67QTVN1PROD with NOTICES ACTION: 60-Day notice. The Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, will be submitting the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for ‘‘sixty days’’ until March 24, 2014. This process is conducted in accordance with 5 CFR 1320.10. If you have comments especially the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Tracey Kyckelhahn, Statistician, Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice, 810 Seventh Street NW., Washington, DC 20531 (phone: 202– 353–7381). Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, VerDate Mar<15>2010 16:00 Jan 21, 2014 Jkt 232001 including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information: (1) Type of information collection: New data collection, Survey of Juveniles Charged in Adult Criminal Court (SJCACC) 2013. (2) The title of the form/collection: Survey of Juveniles Charged in Adult Criminal Court or SJCACC, 2013. (3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form labels are SJCACC–2013, Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice. (4) Affected public who will be asked or required to respond, as well as a brief abstract: State Courts. Abstract: The SJCACC (SJCACC) project will collect accurate and reliable case processing statistics for youth under 18 charged as adults in a nationally representative sample. It will obtain data on demographics of the juvenile, charge information, and method of arrival in adult court (jurisdictional age laws vs. through a transfer mechanism). Adjudication outcomes such as dismissal, guilty plea, and outcome at trial will also be collected, as will sentencing data for those convicted. Fingerprint IDs will be obtained to allow for future recidivism studies and linking with criminal history data. When available, state-wide data will be collected, allowing for some state-bystate comparisons. Juveniles who were transferred to adult court will be oversampled, thus allowing for analyses of the use of different transfer methods. Please see Cost to Federal Government for the financial responsibility associated with the issuance of this report. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that information will be collected on a total of 12,000 felony and misdemeanor defendants from a nationally representative sample that includes states and counties. The estimated burden hours will be contingent upon the state and counties PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 electronic storage and transfer capabilities, with data collection occurring in a more timely and expeditious manner among respondents with the capacities to electronically transfer all their case processing information to the data collection agent. It is estimated 13 states will provide unformatted electronic data files and it should take an average of 56 hours per state. For those 12 states that provide a non-uniform extract, it should take an average of 32 hours, and those 3 states providing a uniform extract will spend on average 80 hours. For the remainder of the nation in which electronic data is not readily available, a sample will be drawn. Eighteen PSUs will be chosen, with approximately 10 responding counties in each PSU. It is estimated that 12 PSUs will have 18 counties with electronic data systems, with an average burden of 12 hours. It is estimated that six PSUs will have nine counties requiring sampling for paper or electronic surveys. An estimated 40 surveys will be required for each of these counties, with an average burden of two hours per survey. It is estimated that 22 states will provide summary statistics of their data, which will be used for weighting and validity checks. (6) An estimate of the total public burden (in hours) associated with the collection: The estimated public burden associated for the SJCACC data collection is a total of 2,310 hours for all of the responding states and counties. If additional information is required contact: Jerri Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., Room 3W– 1407B, Washington, DC 20530. Dated: January 15, 2014. Jerri Murray, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2014–01068 Filed 1–21–14; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (OJJDP) Docket No. 1644] Hearing of the Advisory Committee of the Attorney General’s Task Force on American Indian/Alaska Native Children Exposed to Violence Office of Juvenile Justice and Delinquency Prevention (OJJDP), Justice. ACTION: Notice of hearing. AGENCY: E:\FR\FM\22JAN1.SGM 22JAN1

Agencies

[Federal Register Volume 79, Number 14 (Wednesday, January 22, 2014)]
[Notices]
[Pages 3627-3628]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01158]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application: 
Noramco, Inc.

    Pursuant to 21 CFR 1301.33(a), this is notice that on August 5, 
2013, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 
19801-4417, made application by renewal to the Drug Enforcement 
Administration (DEA) as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053).....................  I
Dihydromorphine (9145).....................  I
Morphine-N-oxide (9307)....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Phenylacetone (8501).......................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Thebaine (9333)............................  II
Opium extracts (9610)......................  II
Opium fluid extract (9620).................  II
Opium tincture (9630)......................  II
Opium, powdered (9639).....................  II
Opium, granulated (9640)...................  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement

[[Page 3628]]

Administration, Office of Diversion Control, Federal Register 
Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 
22152; and must be filed no later than March 24, 2014.

     Dated: January 14, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-01158 Filed 1-21-14; 8:45 am]
BILLING CODE 4410-09-P